Over the past six months, Bristol-Myers Squibb has been a great trade, beating the S&P 500 by 13.7%. Its stock price has climbed to $58.28, representing a healthy 18.8% increase. This run-up might have investors contemplating their next move.
Is now the time to buy Bristol-Myers Squibb, or should you be careful about including it in your portfolio? See what our analysts have to say in our full research report, it’s free.
We’re glad investors have benefited from the price increase, but we don’t have much confidence in Bristol-Myers Squibb. Here are three reasons why BMY doesn’t excite us and a stock we’d rather own.
Founded in 1887, Bristol-Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that develops medicines to treat cancer, immune disorders, and cardiovascular conditions.
Long-term growth is the most important, but within healthcare, a stretched historical view may miss new innovations or demand cycles. Bristol-Myers Squibb’s recent history shows its demand slowed as its annualized revenue growth of 2.3% over the last two years is below its five-year trend.
Adjusted operating margin is one of the best measures of profitability because it tells us how much money a company takes home after subtracting all core expenses, like marketing and R&D. It also removes various one-time costs to paint a better picture of normalized profits.
Looking at the trend in its profitability, Bristol-Myers Squibb’s adjusted operating margin decreased by 30.2 percentage points over the last five years. This raises an eyebrow about the company’s expense base because its revenue growth should have given it leverage on its fixed costs, resulting in better economies of scale and profitability. Its adjusted operating margin for the trailing 12 months was 10.8%.
We track the long-term change in earnings per share (EPS) because it highlights whether a company’s growth is profitable.
Sadly for Bristol-Myers Squibb, its EPS declined by 24.7% annually over the last five years while its revenue grew by 13.1%. This tells us the company became less profitable on a per-share basis as it expanded.
Bristol-Myers Squibb isn’t a terrible business, but it doesn’t pass our quality test. With its shares beating the market recently, the stock trades at 8.5× forward price-to-earnings (or $58.28 per share). While this valuation is optically cheap, the potential downside is big given its shaky fundamentals. We’re fairly confident there are better stocks to buy right now. We’d suggest looking at our favorite semiconductor picks and shovels play.
Story Continues
